

ABUNDANCE INTERNATIONAL LIMITED
(Company Registration No.: 197501572K)
(Incorporated in Singapore)

INCORPORATION OF A NEW SUBSIDIARY

The Board of Directors (the “**Board**”) of Abundance International Limited (the “**Company**”) wishes to announce that the Company’s wholly-owned subsidiary Abundance Specialty Chemicals Pte. Ltd., has incorporated a wholly-owned subsidiary, Abundance Biomedical (Shanghai) Co., Ltd. (“**ABS**”). Details of ABS are as follows:

Name of company	: Abundance Biomedical (Shanghai) Co., Ltd.
Country of incorporation	: People’s Republic of China
Date of establishment	: 1 June 2026
Amount of registered capital	: RMB 3,500,000
Source of Investment	: The funds are derived from internal resources.
Principal activities	: (1) Medical and technological research and development (excluding development and application of human stem cells technologies and gene diagnosis and therapy); (2) Engineering and technological research and development (excluding development and application of human stem cells technologies, gene diagnosis and therapy and China’s rare and endemic genetic resources and superior breeding varieties); (3) Technical services, technology development, technical consulting, technical exchange, technology transfer and technology promotion; and (4) Research and development of bio-based materials technology (excluding activities requiring approval under applicable laws and regulations. The company may independently conduct business activities pursuant to its business licence).

The incorporation of ABS is part of the Company’s strategic initiative in the commercialisation and production of CypH-11 (as announced by the Company in the announcement dated 13 March 2026, “**CypH-11**” has the same meaning as defined therein) in the People’s Republic of China. The Company will make further announcements where there are future developments.

The incorporation of ABS is not expected to have any material impact on the consolidated net tangible assets per share and earnings per share of the Company and the Group for the financial year ending 31 December 2026.

Mr Jiang Hao, an Executive Director of the Company, has been appointed as a Director and the Legal Representative of ABS.

BY ORDER OF THE BOARD

Sam Kok Yin
Managing Director
2 June 2026

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.